---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008293"
form_type: "8-K"
ticker: null
cik: "0001261249"
company_name: "AGILE THERAPEUTICS INC"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:42:17.500530+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agile Therapeutics Q1 net revenue $5.7M (+58% QoQ); GAAP net income of $1.3M

## Summary
- Net revenue $5.7M (+58% QoQ, +50% YoY); GAAP net income $1.3M ($0.28/share) vs. net loss $4.5M in Q4 2023.
- Twirla demand 81,088 cycles (+18% QoQ, +80% YoY); factory sales 70,662 cycles (+3% QoQ, +63% YoY).
- Operating expenses $6.8M (-20% YoY); cash $2.6M as of March 31, 2024.
- Stock now trading on OTC market under symbol AGRX; exploring strategic opportunities.

## SEC filing metadata
- accession: 0001558370-24-008293
- form_type: 8-K
- cik: 0001261249
- company_name: AGILE THERAPEUTICS INC
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1261249/000155837024008293/0001558370-24-008293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1261249/000155837024008293/agrx-20240515x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008293
- JSON: https://secwatch.observer/filing/0001558370-24-008293.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008293.txt

## Key facts
- Earnings Releases
  AGILE THERAPEUTICS INC reported three months ended March 31, 2024 results: revenue $5.7 million, net income $1.3 million, EPS $0.28 per share.
  - Period: three months ended March 31, 2024
  - Revenue: $5.7 million
  - Net income: $1.3 million
  - EPS: $0.28 per share
  - Result: reported results
  source text: Net Revenue: In the first quarter 2024, the Company realized net product sales revenue of $5.7 million, a 58% increase from the fourth quarter 2023 and an increase of 50% as compared to the first quarter of 2023 net revenue of $3.8 million. ● Cost of Goods Sold (COGS) : Cost of goods sold, which consists of direct and indirect costs related to the manufacturing of Twirla, were $1.7 million for the first quarter 2024 compared to the $2.2 million for the fourth quarter 2023 and compared to the $2.0 million for the first quarter 2023. ● Total operating expenses: Total GAAP operating expenses were $6.8 million for the quarter ended March 31, 2024, compared to the $5.5 million for the fourth quarter 2023 and compared to $8.5 million for the comparable period in 2023 – a decrease of 20%. ● GAAP Net income (loss): GAAP net income was $1.3 million, or $0.28 per share, for the quarter ended March 31, 2024, compared to a GAAP net loss of $4.5 million, or $1.51 per share, for the fourth quarter 2
  evidence_url: https://www.sec.gov/Archives/edgar/data/1261249/000155837024008293/0001558370-24-008293-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.